Peptide researchers face a stubborn problem. The molecules they study, including insulin and glucagon-like peptide-1 (GLP-1) analogues, are biologically potent but practically fragile. Enzymes in the gut and bloodstream break them down quickly, the lining of the digestive tract barely lets them through, and their useful window in the body is short. For decades those three obstacles, rapid degradation, poor absorption, and a brief half-life, have kept peptide delivery science busy.
A 2026 review published in the International Journal of Pharmaceutics set out to map where that science now stands. The authors surveyed what they call bioinspired nanoarchitectures: engineered structures that borrow design logic from biology itself, such as the architecture of cell membranes or the way proteins naturally self-assemble into ordered shapes. The goal in each case is the same: protect a peptide long enough for it to reach its target, then release it in a controlled way.
The review covers four broad categories of these platforms, lipid-based carriers, polymer-based systems, peptide-driven self-assembling depots, and stimuli-responsive designs that react to conditions in the body. What follows is a plain-English tour of what researchers in each category have managed to measure so far.
The core delivery problem
To understand why nanoarchitectures matter, it helps to picture what happens when a peptide is swallowed or injected. In the gut, enzymes called proteases treat a peptide like any other protein: something to be broken into amino acids for energy. The mucous layer and tight junctions of the intestinal wall add another barrier, and even peptides that survive digestion may be too large or too hydrophilic to cross into the bloodstream.
Subcutaneous injection sidesteps the gut but introduces its own limits. Once under the skin, many peptides diffuse quickly into circulation, spike in concentration, and then disappear. Researchers studying metabolic and glycaemic endpoints often need sustained, predictable exposure rather than sharp peaks followed by troughs. The review frames all of the nanoarchitecture work it surveys as attempts to solve one or more of these overlapping problems.
Lipid-based nanocarriers
Lipids, the molecules that make up cell membranes, have a natural affinity for biological tissues. Researchers have exploited this by encasing peptides inside lipid nanocarriers that mimic the outer shell of a cell. The review highlights work on hydrophobic ion-paired exenatide lipid nanocarriers, a system in which the GLP-1 analogue exenatide is paired with a fatty counterion to make it more compatible with lipid packaging.
In preclinical models, that approach produced oral bioavailability figures in the range of 16.3 to 27.9 percent. For context, unmodified GLP-1 peptides taken orally typically achieve oral bioavailability well below one percent. The lipid carrier essentially disguises the peptide as something the gut lining is already prepared to absorb. Early data of this kind points to a meaningful gap that formulation science may be able to close, though the review is careful to note that preclinical numbers do not automatically translate to human outcomes.
Polymer-based and stimuli-responsive systems
Polymer systems take a different approach. Instead of mimicking membranes, they wrap peptides in chains of synthetic or semi-synthetic molecules that can be engineered to change behavior depending on the environment they encounter. The review highlights charge-switchable nanoparticle designs in which the surface charge of the carrier flips in response to pH changes as the particle travels through the digestive tract. This switching helps the carrier slip past the mucosal barrier, which repels particles carrying the same charge as the mucus itself.
One polymer construct, described in the review as a PCB122/INS nanoparticle coated capsule, pushed oral insulin bioavailability to approximately 27 percent in animal models. A separate stereocomplex nanoassembly built from D-PLA-PEG polymers achieved something even more striking: a single subcutaneous injection sustained measurable insulin release for up to 16 weeks in type 1 diabetic animal models, while keeping blood glucose within a controlled range across that period. That kind of duration from a single administration has obvious implications for the design of long-term preclinical studies.
Stimuli-responsive designs go one step further by making the release itself conditional. Glucose oxidase-integrated hydrogels and reactive oxygen species (ROS)-responsive polymersomes are two examples the review describes. Under normal glucose conditions these systems stay relatively closed. Under hyperglycaemic conditions, one polymersome platform released more than 90 percent of its insulin payload. The authors use the term closed-loop to describe this behavior because the system senses the problem, in this case high glucose, and responds proportionally, a concept researchers in the field have been chasing for years.
Supramolecular and self-assembling depots
A third category leans on the peptides themselves rather than external packaging materials. Some peptide sequences will spontaneously organize into higher-order structures like fibers or gels when placed in the right conditions. Researchers have exploited this property to create what the review calls supramolecular depots, essentially slow-dissolving reservoirs made partly or entirely from the therapeutic peptide.
GLP-1 nanofibre hydrogels are one example the review examines. When injected, these gels sit at the injection site and release their peptide payload gradually as the fiber network breaks down. In preclinical experiments, sustained glycaemic control from a single administration lasted weeks, and in some cassette-assembled peptide designs the effect extended beyond 40 days. The cassette approach stacks multiple functional peptide sequences together so that the resulting assembly controls both its own degradation rate and the timing of its release.
Cell-based therapies and peptide nanomatrices
The review also touches on an intersection between these delivery platforms and regenerative medicine research. Several of the nanoarchitectures described were studied not just as carriers for soluble peptides but as scaffolds for living cells. Biomimetic pancreatic constructs, combining stem-cell-derived islet cells with peptide-loaded nanomatrices, were tested in type 1 diabetic animal models as a way to restore the cellular machinery that produces insulin rather than simply supplementing it from outside.
This line of research is early and the review presents it as a frontier rather than an established approach. The relevance here is that the same nanoarchitecture principles, controlled degradation, stimuli-responsiveness, membrane mimicry, apply whether the cargo is a peptide molecule or a living cell. The authors frame this convergence as evidence that the engineering logic being developed for peptide delivery has broader reach.
What the review concludes
The review's central argument is that no single platform is likely to be the final answer. Each category, lipid carriers, polymer systems, self-assembling depots, stimuli-responsive designs, addresses a specific subset of the delivery problem, and the most promising results in the literature tend to come from hybrid designs that combine elements from more than one category.
The authors also note that the gap between preclinical results and human outcomes remains a significant research challenge. Bioavailability numbers measured in rodent models do not translate directly, and glucose-responsive systems that perform reliably in controlled laboratory conditions face additional complexity inside a living body where pH, enzyme activity, and glucose concentration all fluctuate. What the body of work surveyed in this review does demonstrate, the authors suggest, is that bioinspired nanoarchitectures give researchers a much richer toolkit for designing and testing peptide delivery strategies than was available even a decade ago. The direction of travel is clear; the distance remaining is the open question.
